myTomorrows Raises $29 Million to Expand Its AI-Powered Platform Connecting Patients to Experimental Therapies

myTomorrows, a health technology company transforming how patients access experimental treatments, has raised $29 million in growth equity funding from Avego. The investment will accelerate the company’s global expansion and fuel the development of its AI-powered platform designed to connect patients, physicians, trial sites, and BioPharma partners in one integrated ecosystem.

With more than 300 million patients worldwide living with conditions that currently lack approved treatment options, myTomorrows is tackling one of medicine’s most urgent gaps: helping patients reach innovative therapies that are still in clinical development or awaiting regulatory approval. The company’s platform acts as a digital bridge between groundbreaking science and those in need, allowing individuals to access clinical trials and expanded access programs that were once difficult to navigate or even discover.

Scaling Access Through AI Innovation

At the heart of myTomorrows’ mission lies its advanced AI infrastructure, built to make healthcare navigation more intelligent, transparent, and equitable. The company’s algorithms continuously analyze data from thousands of clinical trials and regulatory filings to identify potential matches between patients and emerging therapies. This approach dramatically shortens the time it takes for physicians to locate relevant treatment opportunities while improving the accuracy of recommendations.

The new funding will enable myTomorrows to further develop these capabilities—enhancing its use of machine learning models to streamline physician referrals, support regulatory insight, and strengthen evidence generation for BioPharma partners. The platform’s AI tools not only speed up access but also help pharmaceutical companies identify gaps in trial participation, accelerating the overall pace of clinical research.

“Our goal has always been to give every patient, regardless of where they live, a fair shot at tomorrow’s therapies,” said Michel van Harten, CEO of myTomorrows. “With Avego’s support and expertise in life sciences, we can scale our AI systems globally, strengthen our data-driven insights, and ultimately help more patients access promising experimental treatments.”

Avego’s Managing Partner, James Flexner, echoed this sentiment, noting that “myTomorrows is uniquely positioned to remove barriers for patients and providers while serving as an essential partner to BioPharma. Their AI-driven approach redefines how clinical access and real-world data come together.”

A Global Network Empowering Patients and Physicians

Since its founding in 2012, myTomorrows has helped more than 16,900 patients across 133 countries access experimental therapies that would otherwise remain out of reach. Its AI-powered system integrates personalized human guidance with automated data analysis to match patients to the most suitable programs, whether they are clinical trials or expanded access opportunities.

For physicians, the platform serves as a decision-support tool, simplifying an often complex and fragmented process. For BioPharma companies, myTomorrows provides recruitment and data management solutions that improve trial efficiency and compliance. The system also enables real-time visibility for trial sites, allowing seamless coordination between participants, clinicians, and sponsors.

Dr. Ronald Brus, the company’s founder and board member, emphasized the long-term vision behind this approach: “When we started myTomorrows, we imagined a world where patients could easily connect with innovation, and where data from these experiences could meaningfully accelerate drug development. This new investment marks a turning point—moving from possibility to global impact.”

AI as the Engine of Healthcare Transformation

Beyond its immediate clinical applications, myTomorrows represents a broader movement toward AI-enabled healthcare ecosystems that connect disparate players—from researchers and regulators to hospitals and patients—through shared intelligence. The company’s system captures real-world data on patient outcomes, which can inform regulatory decisions, guide R&D, and ultimately refine the design of future trials.

As the boundaries between digital health and traditional medicine blur, this type of AI-driven transparency and coordination could redefine how therapies are brought to market. Instead of waiting years for new drugs to complete approval cycles, patients could gain controlled access to promising treatments while data continues to feed into clinical validation pipelines.

This approach hints at a future where AI acts as the connective tissue of global medicine—enabling dynamic, data-informed collaboration between patients, doctors, and pharmaceutical innovators. For millions of people facing life-threatening or rare diseases, that future may arrive not in decades, but in years.

“AI is no longer just a supporting tool in healthcare,” van Harten added. “It’s becoming the foundation for how we connect innovation with human need. Our mission is to ensure that no promising therapy sits on a shelf when it could be in a patient’s hands.”

The Road Ahead

With Avego’s backing and a decade of groundwork laid, myTomorrows is now entering its most ambitious chapter—building the infrastructure for AI-powered access to experimental medicine at a global scale. The company’s continued focus on responsible data use, transparent patient engagement, and partnership with BioPharma leaders positions it at the forefront of the next era in healthcare delivery.

If successful, its model could shift how the world views drug development—not as a linear process that ends with regulatory approval, but as an adaptive, data-rich ecosystem where AI and human expertise work together to ensure that innovation reaches patients when they need it most.